AZRX - AzurRx Bio activates additional trial sites for lead candidate

AzurRx BioPharma ([[AZRX]]) has activated two trial sites in Turkey for its Phase 2 trial, evaluating MS1819 combined with porcine pancreatic enzyme replacement therapy ((PERT)), in cystic fibrosis ((CF)) patients with severe exocrine pancreatic insufficiency ((EPI)). A total of eight of the expected twelve sites in Europe are now active and recruiting patients.Planned enrollment is expected to include ~24 CF patients with severe EPI, with study completion anticipated in Q2 2021.In August, the company announced positive interim data from the trial

For further details see:

AzurRx Bio activates additional trial sites for lead candidate